Vanguard Fiduciary Trust
INKT icon

Vanguard Fiduciary Trust’s MiNK Therapeutics INKT Stock Holding History

Vanguard Fiduciary Trust’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$96.9K Hold
8,287
– – ﹤0.01% 3745
2026
Q1 		$87.3K Buy
+8,287
New +$92.4K ﹤0.01% 3737

Other funds holding INKT

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DnB Asset Management
DnB Asset Management Oslo, Norway $35.7B AUM 27.58% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return
PP
Paladin Partners Hartland, Wisconsin $151M AUM

Vanguard Fiduciary Trust's INKT Position: Q2 2026 in Review

Vanguard Fiduciary Trust held its MiNK Therapeutics (INKT) position steady in Q2 2026 at 8,287 shares worth $96.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3745.

Vanguard Fiduciary Trust first reported a position in INKT in Q1 2026 and has held it in 2 quarters since. 28 funds tracked by Wall St. Rank hold INKT as of Q2 2026.

  • Vanguard Fiduciary Trust held 8,287 shares of MiNK Therapeutics worth $96.9K as of Q2 2026.
  • Vanguard Fiduciary Trust left its MiNK Therapeutics share count unchanged in Q2 2026.
  • MiNK Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3745 holding.
  • Vanguard Fiduciary Trust first reported a position in MiNK Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 28 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.